Patents Assigned to Niigata University
  • Patent number: 12291710
    Abstract: The present invention provides an antisense oligonucleotide that is formed of 15-22 nucleotides and that is complementary to a nucleic acid including at least 15 consecutive bases in a specific target region of a base sequence of SEQ ID NO: 471 (which encodes atrophin 1; ATN1), or a pharmaceutically acceptable salt thereof, or a hydrate thereof.
    Type: Grant
    Filed: June 12, 2024
    Date of Patent: May 6, 2025
    Assignees: Nippon Shinyaku Co., Ltd., Niigata University
    Inventors: Takao Kawano, Toshiaki Ode, Akie Chiba, Osamu Onodera, Taisuke Kato, Sachiko Hirokawa
  • Patent number: 12239621
    Abstract: One object of the present invention is to provide an inhibitor for renal injuries induced by a hemolytic reaction. In this invention, cilastatin or a pharmaceutically acceptable salt thereof is used.
    Type: Grant
    Filed: March 8, 2022
    Date of Patent: March 4, 2025
    Assignees: Niigata University, Denka Company Limited
    Inventors: Akihiko Saito, Sawako Goto, Yoshiaki Hirayama
  • Publication number: 20240299496
    Abstract: The present inventors have discovered that a peptide derived from HMGB1 can be used as a therapeutic and/or preventive agent for fatty liver, nonalcoholic steatohepatitis, and various symptoms accompanied by the fatty liver. On the basis of this discovery, the present application provides a use of the peptide derived from HMGB1 which is different from conventional uses.
    Type: Application
    Filed: September 30, 2022
    Publication date: September 12, 2024
    Applicants: Osaka University, Niigata University, StemRIM Inc.
    Inventors: Katsuto TAMAI, Takashi SHIMBO, Shuji TERAI, Atsunori TSUCHIYA, Takehiko YAMAZAKI
  • Patent number: 11869190
    Abstract: A method, a program, and a method determining hypermutated type cancer with higher accuracy than before is provided.
    Type: Grant
    Filed: April 4, 2022
    Date of Patent: January 9, 2024
    Assignees: Niigata University, Denka Company Limited
    Inventors: Toshifumi Wakai, Shujiro Okuda, Yoshifumi Shimada, Hiroshi Izutsu, Keisuke Kodama
  • Patent number: 11858984
    Abstract: Provided is a substance capable of effectively suppressing cancer metastasis or a pharmaceutical composition that effectively acts on an inflammatory disease. The pharmaceutical composition is a pharmaceutical composition containing, as an active ingredient, an antibody or an antibody fragment thereof having antigen-binding activity for an S100A8/A9 heterodimer, and blocks interaction between S100A8/A9 and a group of receptors therefor, to thereby strongly suppress cancer metastasis both in vitro and in vivo, or alleviate inflammation. That is, the anti-S100A8/A9 antibody or the antibody fragment thereof can strongly suppress cancer metastasis or alleviate inflammation, by virtue of its blocking action on the interaction between S100A8/A9 and the group of receptors therefor.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: January 2, 2024
    Assignees: National University Corporation Okayama University, Niigata University, National University Corporation Gunma University
    Inventors: Masakiyo Sakaguchi, Shinichi Toyooka, Shuta Tomida, Kazuhiko Shien, Hiroki Sato, Rie Kinoshita, Junichiro Futami, Kota Araki, Mikio Okazaki, Eisaku Kondo, Yusuke Inoue, Akira Yamauchi
  • Publication number: 20230366890
    Abstract: The present invention provides a method of assisting a determination of whether a subject is susceptible to infection by norovirus or whether a subject is susceptible to post-infection worsening, wherein this method contains a step of measuring the concentration of IgG antibody that is present in a sample originating from within the oral cavity of the subject.
    Type: Application
    Filed: October 7, 2021
    Publication date: November 16, 2023
    Applicants: Niigata University, Denka Company Limited
    Inventors: Akihiko SAITO, Michihiro HOSOJIMA, Hideyuki KABASAWA, Nobumasa AOKI, Kei NAGANO, Sakari SEKINE, Keisuke MUNEKATA
  • Publication number: 20220301167
    Abstract: A method, a program, and a method determining hypermutated type cancer with higher accuracy than before is provided.
    Type: Application
    Filed: April 4, 2022
    Publication date: September 22, 2022
    Applicants: Niigata University, Denka Company Limited
    Inventors: Toshifumi Wakai, Shujiro Okuda, Yoshifumi Shimada, Hiroshi Izutsu, Keisuke Kodama
  • Patent number: 11414655
    Abstract: An object of the present invention is to provide a method for preparing ambrein, which can easily and efficiently obtain the ambrein. The object can be solved by a mutated tetraprenyl-?-curcumene cyclase wherein (1) a 4th amino acid residue of a DXDD motif, aspartic acid, is substituted with an amino acid other than aspartic acid, and (2) an amino acid adjacent to the N-terminus of a (A/S/G)RX(H/N)XXP motif is substituted with an amino acid other than tyrosine, or a 4th amino acid of the GXGX(G/A/P) motif is substituted with an amino acid other than leucine.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: August 16, 2022
    Assignees: Niigata University, Adeka Corporation
    Inventors: Tsutomu Sato, Tsutomu Hoshino, Toshihiko Takehana, Seiji Koike, Koichi Shigeno
  • Patent number: 11295447
    Abstract: A method, a program, and a method determining hypermutated type cancer with higher accuracy than before is provided.
    Type: Grant
    Filed: February 7, 2019
    Date of Patent: April 5, 2022
    Assignees: Niigata University, Denka Company Limited
    Inventors: Toshifumi Wakai, Shujiro Okuda, Yoshifumi Shimada, Hiroshi Izutsu, Keisuke Kodama
  • Publication number: 20210163537
    Abstract: This peptide is composed of an amino acid sequence represented by general formula (I), and has a high degree of accumulation in cancer cells or cancer tissue in a digestive system. (In general formula (I), X11 is a peptide residue composed of an amino acid sequence of (a) or (b) below: (a) an amino acid sequence represented by any of SEQ ID NOs: 1 to 3, (b) an amino acid sequence including a sequence in which one or two amino acids have been deleted, substituted or added in an amino acid sequence represented by any of SEQ m NOs: 1 to 3; Y11 is a peptide linker composed of an amino acid residue of at least 1 but not more than 10 amino acids, wherein each amino acid residue is independently a glycine residue, a proline residue, a serine residue a cysteine residue or a lysine residue; X12 is either a peptide residue composed of an amino acid sequence of (a) or (b) above, or a retro-inverso peptide residue thereof; and n11 represents an integer of at least 1 but not more than 9.
    Type: Application
    Filed: April 25, 2019
    Publication date: June 3, 2021
    Applicant: Niigata University
    Inventors: Eisaku KONDO, Ken SAITO
  • Publication number: 20210045195
    Abstract: An infrared radiation device includes a body including a heat generating part and first and second metamaterial structures that are capable of radiating infrared rays having a peak wavelength of a non-Planck distribution upon receipt of thermal energy from the heat generating part. The first metamaterial structure is disposed on a first surface side of the heat generating part, and the second metamaterial structure is disposed on a second surface side opposite to the first surface side of the heat generating part.
    Type: Application
    Filed: October 19, 2020
    Publication date: February 11, 2021
    Applicants: NGK Insulators, Ltd., National University Corporation Hokkaido University, Niigata University
    Inventors: Michiro AOKI, Yoshio KONDO, Tsuyoshi TOTANI, Atsushi SAKURAI
  • Publication number: 20210035300
    Abstract: A method, a program, and a method determining hypermutated type cancer with higher accuracy than before is provided.
    Type: Application
    Filed: February 7, 2019
    Publication date: February 4, 2021
    Applicants: Niigata University, Denka Company Limited
    Inventors: Toshifumi Wakai, Shujiro Okuda, Yoshifumi Shimada, Hiroshi Izutsu, Keisuke Kodama
  • Publication number: 20200354754
    Abstract: An object of the present invention is to provide a method for preparing ambrein, which can easily and efficiently obtain the ambrein. The object can be solved by a mutated tetraprenyl-?-curcumene cyclase wherein (1) a 4th amino acid residue of a DXDD motif, aspartic acid, is substituted with an amino acid other than aspartic acid, and (2) an amino acid adjacent to the N-terminus of a (A/S/G)RX(H/N)XXP motif is substituted with an amino acid other than tyrosine, or a 4th amino acid of the GXGX(G/A/P) motif is substituted with an amino acid other than leucine.
    Type: Application
    Filed: August 31, 2018
    Publication date: November 12, 2020
    Applicants: Niigata University, Adeka Corporation
    Inventors: Tsutomu Sato, Tsutomu Hoshino, Toshihiko Takehana, Seiji Koike, Koichi Shigeno
  • Patent number: 10668125
    Abstract: Disclosed is a peptide of the following (a) or (b): (a) a peptide containing an amino acid sequence including a sequence set forth in any one of SEQ ID NOS: 1, 2, 3, and 4; and (b) a peptide containing an amino acid sequence including a sequence having at least 60% identity with a sequence set forth in any one of SEQ ID NOS: 1, 2, 3, and 4, the peptide having highly-shifted accumulation to pancreatic cancer cells and tissues.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: June 2, 2020
    Assignee: Niigata University
    Inventors: Eisaku Kondo, Ken Saito
  • Patent number: 10420741
    Abstract: The present invention includes cilastatin or a pharmaceutically acceptable salt thereof as an active component and a suppressant for renal impairment or inner ear disorders, induced via megalin by at least one megalin ligand which is selected from the group consisting of polymyxins, aminoglycoside antibiotics, glycopeptide antibiotics, cisplatin, and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: September 24, 2019
    Assignees: EA Pharma Co., Ltd., Niigata University
    Inventors: Akihiko Saito, Nobumasa Aoki, Yoshihisa Hori, Shoji Kuwahara, Michihiro Hosojima, Hiroshi Iwata, Saori Matsuda
  • Publication number: 20190246457
    Abstract: An infrared heater includes a heater body and a casing. The heater body includes a heating element and a metamaterial structure capable of emitting infrared radiation having a peak wavelength of a non-Planck distribution when thermal energy is supplied from the heating element. The casing has an interior space in which the heater body is disposed and whose pressure is reducible. In addition, the casing includes an infrared radiation transmitting portion capable of transmitting the infrared radiation emitted by the metamaterial structure to an outside of the casing.
    Type: Application
    Filed: April 17, 2019
    Publication date: August 8, 2019
    Applicants: NGK INSULATORS, LTD., National University Corporation Hokkaido University, National University Corporation Niigata University
    Inventors: Michiro AOKI, Yoshio Kondo, Tsuyoshi Totani, Atsushi Sakurai
  • Publication number: 20190078120
    Abstract: An object of the present invention is to provide a method for preparing ambrein, which can easily obtain the ambrein. The object can be solved by a mutated tetraprenyl-?-curcumene cyclase wherein a fourth amino acid residue of a DXDD motif, aspartic acid, is substituted with an amino acid other than aspartic acid, (a) having a QXXXGX(W/F) motif, and a QXXXX(G/A)X(F/W/Y) motif on the N-terminal side, and a QXXXGX(F/W/Y) motif, and a QXXXGXW motif and a QXXXGX(F/W) motif on the C-terminal side, and not having a QXXXGXW motif at a position separated by 170 amino acid residues or more on the C-terminal side, with respect to the DXDD motif, (b) having 40% or more identity with the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 13, (c) exhibiting ambrein production activity using squalene as a substrate.
    Type: Application
    Filed: March 3, 2017
    Publication date: March 14, 2019
    Applicants: Niigata University, Adeka Corporation
    Inventors: Tsutomu SATO, Kotone OKUNO, Toshihiko TAKEHANA, Seiji KOIKE
  • Publication number: 20180360903
    Abstract: The present invention provides a novel peptide that acts directly on pancreatic cancer cells and tissues and has highly-shifted accumulation thereto. Disclosed is a peptide of the following (a) or (b): (a) a peptide containing an amino acid sequence including a sequence set forth in any one of SEQ ID NOS:1, 2, 3, and 4; and (b) a peptide containing an amino acid sequence including a sequence having at least 60% identity with a sequence set forth in any one of SEQ ID NOS:1, 2, 3, and 4, the peptide having highly-shifted accumulation to pancreatic cancer cells and tissues.
    Type: Application
    Filed: October 21, 2016
    Publication date: December 20, 2018
    Applicant: Niigata University
    Inventors: Eisaku Kondo, Ken Saito
  • Publication number: 20180357930
    Abstract: Provided is a pseudo visceral model having a specific texture. A model of viscera, tissues, or organs comprising a foam layer containing a hydrogel.
    Type: Application
    Filed: December 2, 2016
    Publication date: December 13, 2018
    Applicants: SUNARROW LTD, Niigata University
    Inventors: Yutaka Kuwabara, Atsushi Ogawa, Ken-ichi Mizuno, Hiroki Sato, Shuji Terai
  • Patent number: 9902979
    Abstract: Provided is a method for producing ambrein, comprising reacting tetraprenyl-?-curcumene cyclase with 3-deoxyachilleol A to obtain ambrein.
    Type: Grant
    Filed: August 12, 2014
    Date of Patent: February 27, 2018
    Assignee: Niigata University
    Inventors: Tsutomu Sato, Daijiro Ueda, Tsutomu Hoshino